News Releases Year None2026202520242023202220212020201920182017 NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update Mar 19, 2026 NuCana Appoints Theresa Bruce as Chief Operating Officer Jan 06, 2026 NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma Dec 10, 2025 NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update Nov 13, 2025 NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China Nov 05, 2025 NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 Oct 18, 2025 NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy Oct 14, 2025 NuCana Compliant with All Nasdaq Continued Listing Criteria Sep 05, 2025 NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 Sep 03, 2025 NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update Aug 20, 2025 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update Mar 19, 2026
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma Dec 10, 2025
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 Oct 18, 2025
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 Sep 03, 2025